
Tao Shen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10915726/publications.pdf Version: 2024-02-01



TAO SHEN

#	Article	IF	CITATIONS
1	The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. Npj Precision Oncology, 2021, 5, 48.	2.3	30
2	Iron chelation inhibits mTORC1 signaling involving activation of AMPK and REDD1/Bnip3 pathways. Oncogene, 2020, 39, 5201-5213.	2.6	18
3	RET kinase alterations in targeted cancer therapy. , 2020, 3, 472-481.		7
4	Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. Journal of Biological Chemistry, 2019, 294, 10428-10437.	1.6	43
5	Drug resistance profiles of mutations in the RET kinase domain. British Journal of Pharmacology, 2018, 175, 3504-3515.	2.7	61
6	Ciclopirox activates ATR-Chk1 signaling pathway leading to Cdc25A protein degradation. Genes and Cancer, 2018, 9, 39-52.	0.6	13
7	Ciclopirox inhibits cancer cell proliferation by suppression of Cdc25A. Genes and Cancer, 2017, 8, 505-516.	0.6	29
8	Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma. Molecular Cancer Therapeutics, 2016, 15, 2521-2529.	1.9	63
9	Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK. Biochemical Pharmacology, 2016, 116, 39-50.	2.0	26
10	Repositioning the Old Fungicide Ciclopirox for New Medical Uses. Current Pharmaceutical Design, 2016, 22, 4443-4450.	0.9	41
11	Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells. Carcinogenesis, 2014, 35, 192-200.	1.3	49
12	Ciclopirox induces autophagy through reactive oxygen species-mediated activation of JNK signaling pathway. Oncotarget, 2014, 5, 10140-10150.	0.8	75
13	Curcumin inhibits protein phosphatases 2A and 5, leading to activation of mitogen-activated protein kinases and death in tumor cells. Carcinogenesis, 2012, 33, 868-875.	1.3	68
14	The Role of Cdc25A in the Regulation of Cell Proliferation and Apoptosis. Anti-Cancer Agents in Medicinal Chemistry, 2012, 12, 631-639.	0.9	154
15	Rapamycin Inhibits Lymphatic Endothelial Cell Tube Formation by Downregulating Vascular Endothelial Growth Factor Receptor 3 Protein Expression. Neoplasia, 2012, 14, 228-237.	2.3	60
16	Cryptotanshinone Activates p38/JNK and Inhibits Erk1/2 Leading to Caspase-Independent Cell Death in Tumor Cells. Cancer Prevention Research, 2012, 5, 778-787.	0.7	68
17	Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death. Free Radical Biology and Medicine, 2011, 50, 624-632.	1.3	214
18	Cryptotanshinone Inhibits Lymphatic Endothelial Cell Tube Formation by Suppressing VEGFR-3/ERK and Small GTPase Pathways. Cancer Prevention Research, 2011, 4, 2083-2091.	0.7	20

TAO SHEN

#	Article	IF	CITATIONS
19	Calcium Signaling Is Involved in Cadmium-Induced Neuronal Apoptosis via Induction of Reactive Oxygen Species and Activation of MAPK/mTOR Network. PLoS ONE, 2011, 6, e19052.	1.1	158
20	The antitumor activity of the fungicide ciclopirox. International Journal of Cancer, 2010, 127, 2467-2477.	2.3	88
21	Hydrogen peroxide inhibits mTOR signaling by activation of AMPKα leading to apoptosis of neuronal cells. Laboratory Investigation, 2010, 90, 762-773.	1.7	207
22	Rapamycin Inhibits IGF-1 Stimulated Cell Motility through PP2A Pathway. PLoS ONE, 2010, 5, e10578.	1.1	36
23	Rapamycin Inhibits Cytoskeleton Reorganization and Cell Motility by Suppressing RhoA Expression and Activity. Journal of Biological Chemistry, 2010, 285, 38362-38373.	1.6	120
24	Cryptotanshinone Inhibits Cancer Cell Proliferation by Suppressing Mammalian Target of Rapamycin–Mediated Cyclin D1 Expression and Rb Phosphorylation. Cancer Prevention Research, 2010, 3, 1015-1025.	0.7	97